NewsBenzinga오펜하이머, 팔벨라 테라퓨틱스에 대한 ‘시장수익률 상회’ 의견 유지···목표주가 232달러로 상향 오펜하이머, 팔벨라 테라퓨틱스에 대한 ‘시장수익률 상회’ 의견 유지···목표주가 232달러로 상향 Benzinga 2026.11.06 17:24 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 Ex-Carlyle Executive Launches Asia Secondaries Firm as $3 Trillion Sits Locked in Private Funds 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report